Core Viewpoint - The company, Amgen Pharmaceuticals (688373.SH), has announced that its shareholders, Best Idea, JSR, and GP TMT, plan to reduce their holdings by up to 39.3363 million shares, representing no more than 6% of the total share capital, primarily due to personal funding needs [1] Summary by Relevant Categories Shareholder Actions - Shareholders Best Idea, JSR, and GP TMT intend to reduce their holdings through centralized bidding and block trading [1] - The total number of shares to be reduced is up to 39.3363 million [1] Market Impact - The reduction in shares will be executed at market prices, indicating a potential impact on the stock's market performance [1] - The planned reduction reflects the shareholders' personal funding requirements rather than company performance issues [1]

Core Viewpoint - Mengke Pharmaceutical (688373.SH) announced that shareholders BestIdea, JSR, and GPTMT plan to reduce their holdings by up to 39.34 million shares, representing no more than 6% of the company's total share capital, primarily due to personal funding needs [1] Summary by Relevant Categories Shareholder Actions - Shareholders BestIdea, JSR, and GPTMT intend to reduce their stakes in the company through centralized bidding and block trading [1] - The total number of shares to be reduced is up to 39.34 million [1] Company Capital Structure - The planned reduction accounts for a maximum of 6% of the company's total share capital [1]

盟科药业(688373.SH)发布公告，公司于近日收到Best Idea、JSR及GP TMT出具的《关于股东减持计划 的告知函》，股东Best Idea、JSR及GPTMT计划根据市场情况拟通过集中竞价交易和大宗交易方式减持 其所持有的公司股份合计不超过3933.63万股，即不超过公司总股本的6%。 ...

证券代码：688373 证券简称：盟科药业 公告编号：2025-038 上海盟科药业股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 一、减持主体的基本情况 | | | 1 大股东持股的基本情况：截至本公告披露日，上海盟科药业股份有限 公司（以下简称"公司"）股东 Best Idea International Limited（以下简 称"Best Idea"）持有公司股份 58,439,004 股，占公司股份总数的 8.91%； 股东 JSR Limited（以下简称"JSR"）持有公司股份 30,844,484 股，占 公司股份总数的 4.70%；股东 GP TMT Holdings Limited（以下简称"GP TMT"）持有公司股份 18,371,317 股，占公司股份总数的 2.80%。JSR 与 GP TMT 为一致行动人，二者合计持有公司股份 49,215,801 股，占 公司股份总数 7.51%。上述股份均为公司首次公开发行并上市前取得的 股份 ...

人民财讯9月9日电，盟科药业(688373)9月9日晚间公告，持股8.91%的股东Best Idea International Limited、持股4.70%的股东JSR Limited及持股2.80%的股东GP TMT Holdings Limited计划根据市场情况 拟通过集中竞价交易和大宗交易方式减持其所持有的公司股份合计不超过3933.63万股，即不超过公司 总股本的6%。 ...

中国国际金融股份有限公司 三、重大风险事项 关于上海盟科药业股份有限公司 2025 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》（以下简称"《保荐办法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上市公司持续监管办法 （试行）》等有关法律、法规的规定，中国国际金融股份有限公司（以下简称"保荐机 构"）作为上海盟科药业股份有限公司（以下简称"盟科药业"或"公司"）持续督导工 作的保荐机构，负责盟科药业上市后的持续督导工作，并出具 2025 年半年度持续督导 跟踪报告，本持续督导期间为 2025 年 1 月 1 日至 2025 年 6 月 30 日。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并 针对具体的持续督导工作制定相应的工作计 | 保荐机构已建立健全并有效执行了持续督导 | | | | 制度，并制定了相应的工作计划。 | | | 划。 | | | 2 | 根据中国证监会相关规定，在持续督导工作 | 保荐机构已与盟科药业签订《保荐协议》，该 协议明确了双方在持续 ...

Group 1 - Major stock indices rebounded collectively after three days of adjustment, with most sectors showing gains [1] - The disclosure of mid-year reports from listed companies has clarified the investment strategies of prominent investors, leading to significant floating profits [1][3] - Zhao Jianping, known as a "perennial tree" among A-share investors, appeared in the top ten shareholders of ten A-share companies by the end of Q2, with three new heavy positions and seven ongoing ones [3] Group 2 - Zhao Jianping's total market value of holdings in ten A-share companies reached 861 million yuan by the end of Q2, which increased to 1.335 billion yuan by September 4, resulting in a floating profit of 474 million yuan [5] - The stock price of Dongxin Co., a new heavy position for Zhao Jianping, has doubled in just over a month, with a total increase of over 300% since April 8 [4][5] - Zhao Jianping's holdings in innovative drug and technology stocks have shown strong performance, with several stocks gaining over 50% during the same period [4][6] Group 3 - The innovative drug sector has been receiving positive news, with multiple Chinese pharmaceutical companies set to showcase their innovations at the World Lung Cancer Conference in September 2025 [9] - BlackRock increased its stake in Sanofi Pharmaceutical, while GIC acquired a significant stake in Base Pharmaceuticals, indicating growing interest in the innovative drug sector [9] - The technology sector, particularly in artificial intelligence and chips, has also seen a rebound, with Zhao Jianping increasing his holdings in several key stocks [11][12]

Group 1 - The company, Mengke Pharmaceutical, announced its participation in the 2025 semi-annual performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [2]

Group 1 - The company will participate in the 2025 semi-annual performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [2][3] - The briefing will be held in an online interactive format at the Shanghai Stock Exchange Roadshow Center [2][3] - Key personnel attending the briefing include Chairman and General Manager Zhengyu Yuan, CFO Li Zhile, Independent Director Zhang Huaiying, and Secretary of the Board Nie Anna [2] Group 2 - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date [2][3] - Investors are encouraged to submit questions from September 9 to September 15, 2025, through the designated online platform or via the company's email [3] - After the briefing, investors can view the main content and outcomes of the event on the Shanghai Stock Exchange Roadshow Center [3]

证券代码：688373 证券简称：盟科药业 公告编号：2025-037 上海盟科药业股份有限公司 关于参加 2025 年半年度科创板创新药行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 16 日 （星期二） 15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 本次业绩说明会以网络互动形式召开，公司将针对 2025 年半年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 09 月 16 日 （星期二） 15:00-17:00 （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://ro ...